Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 1
Submit an article Journal homepage
63
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Dose reduction and high-risk disease as risk factors for early death in primary CNS lymphoma

Vanja ZeremskiDepartment of Hematology and Oncology, Medical Center, Otto-von-Guericke University Magdeburg, Magdeburg, Germany; ;Health Campus Immunology, Infectiology and Inflammation (GC-I³), Medical Center, Otto-von-Guericke University, Magdeburg, GermanyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-5254-9885View further author information
ORCID Icon,
Thomas FischerDepartment of Hematology and Oncology, Medical Center, Otto-von-Guericke University Magdeburg, Magdeburg, Germany; ;Health Campus Immunology, Infectiology and Inflammation (GC-I³), Medical Center, Otto-von-Guericke University, Magdeburg, GermanyView further author information
&
Enrico SchalkDepartment of Hematology and Oncology, Medical Center, Otto-von-Guericke University Magdeburg, Magdeburg, Germany; ;Health Campus Immunology, Infectiology and Inflammation (GC-I³), Medical Center, Otto-von-Guericke University, Magdeburg, GermanyView further author information
Pages 240-242 | Received 03 Jun 2019, Accepted 23 Jul 2019, Published online: 08 Aug 2019

References

  • Mendez JS, Ostrom QT, Gittleman H, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20:687–694.
  • Bairey O, Bar-Natan M, Shpilberg O. Early death in patients diagnosed with non-Hodgkin's lymphoma. Ann Hematol. 2013;92:345–350.
  • Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711–5715.
  • Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266–272.
  • Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036–1047.
  • Zeremski V, Koehler M, Fischer T, et al. Characteristics and outcome of patients with primary CNS lymphoma in a “real-life” setting compared to a clinical trial. Ann Hematol. 2016;95:793–799.
  • Ghesquières H, Drouet Y, Sunyach MP, et al. Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients. Hematol Oncol. 2013;31:57–64.
  • Han X, Ji Y, Ouyang M, et al. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese. Sci Rep. 2017;7:17053.
  • Othus M, Kantarjian H, Petersdorf S, et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. Leukemia. 2014;28:289–292.
  • Haldorsen IS, Espeland A, Larsen JL, et al. Diagnostic delay in primary central nervous system lymphoma. Acta Oncol. 2005;44:728–734.
  • Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113:28–36.
  • Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010;116:5103–5110.
  • Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31:3061–3068.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.